Medical Engineering Innovations, Inc.
MEI is developing procedure-specific RF surgical tools for nearly bloodless treatment of liver cancer, kidney cancer and uterine fibroids.
MEI is developing surgical tools to resolve unmet needs and improve patient outcomes, primarily in the area of cancer treatment. Our core technology, SwiftBlade, is focused on minimizing blood loss during liver resections. We believe this technology will also provide substantial benefit when applied to partial nephrectomies and the treatment of uterine fibroids. Globally, the market potential for this product family is $3.6 billion.